PUBLICATION

Multivalent insulin receptor activation using insulin-DNA origami nanostructures

Authors
Spratt, J., Dias, J.M., Kolonelou, C., Kiriako, G., Engström, E., Petrova, E., Karampelias, C., Cervenka, I., Papanicolaou, N., Lentini, A., Reinius, B., Andersson, O., Ambrosetti, E., Ruas, J.L., Teixeira, A.I.
ID
ZDB-PUB-231010-60
Date
2023
Source
Nature nanotechnology   19(2): 237-245 (Journal)
Registered Authors
Andersson, Olov, Karampelias, Christos
Keywords
none
MeSH Terms
  • Animals
  • DNA*/chemistry
  • Diabetes Mellitus/drug therapy
  • Insulin
  • Nanostructures*/chemistry
  • Receptor, Insulin*/drug effects
  • Receptor, Insulin*/metabolism
  • Zebrafish
PubMed
37813939 Full text @ Nat Nanotechnol
Abstract
Insulin binds the insulin receptor (IR) and regulates anabolic processes in target tissues. Impaired IR signalling is associated with multiple diseases, including diabetes, cancer and neurodegenerative disorders. IRs have been reported to form nanoclusters at the cell membrane in several cell types, even in the absence of insulin binding. Here we exploit the nanoscale spatial organization of the IR to achieve controlled multivalent receptor activation. To control insulin nanoscale spatial organization and valency, we developed rod-like insulin-DNA origami nanostructures carrying different numbers of insulin molecules with defined spacings. Increasing the insulin valency per nanostructure markedly extended the residence time of insulin-DNA origami nanostructures at the receptors. Both insulin valency and spacing affected the levels of IR activation in adipocytes. Moreover, the multivalent insulin design associated with the highest levels of IR activation also induced insulin-mediated transcriptional responses more effectively than the corresponding monovalent insulin nanostructures. In an in vivo zebrafish model of diabetes, treatment with multivalent-but not monovalent-insulin nanostructures elicited a reduction in glucose levels. Our results show that the control of insulin multivalency and spatial organization with nanoscale precision modulates the IR responses, independent of the insulin concentration. Therefore, we propose insulin nanoscale organization as a design parameter in developing new insulin therapies.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping